Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Investigator Sponsored Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses Followed by Dose Expansion of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Asian Patients With Advanced or Metastatic Solid Tumor Malignancies

Next Previous
Trial Profile

An Investigator Sponsored Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses Followed by Dose Expansion of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Asian Patients With Advanced or Metastatic Solid Tumor Malignancies

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 21 Apr 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Selinexor (Primary)
  • Indications Advanced breast cancer; B-cell lymphoma; Carcinoma; Cholangiocarcinoma; Colorectal cancer; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Gastric cancer; Gynaecological cancer; Head and neck cancer; Hodgkin's disease; Liver cancer; Lung cancer; Malignant thymoma; Nasopharyngeal cancer; Ovarian cancer; Pancreatic cancer; Solid tumours; Tongue cancer
  • Focus Adverse reactions

Most Recent Events

  • 02 Mar 2021 Results presented at the 19th International Congress on Targeted Anticancer Therapies.
  • 08 Sep 2020 Status changed from recruiting to completed.
  • 11 Oct 2016 Results (N=18) of colorectal cancer patients presented at the 41st European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top